Medline shares slip as investors weigh secondary-sale overhang and recent FDA quality action

Medline Inc. (MDLN) is down 4.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The pullback looks tied to supply/overhang concerns after a very large sponsor-led secondary sale, combined with lingering investor caution around a recent FDA warning letter and related device removal activity. With the stock still relatively new to public markets, incremental headlines on selling and compliance can have an outsized impact on day-to-day trading.

Details:

Medline disclosed the closing of a secondary offering totaling 86,250,000 Class A shares at $41.00, sold by existing stockholders; the company said it did not sell shares and did not receive proceeds.

The FDA posted a warning letter (dated March 25, 2026) to Medline Industries, LP that cited quality-system issues tied to certain NAMIC-branded angiographic control syringes and related actions.

The FDA also published recall-related information advising removal of certain NAMIC Angiographic Rotating Adaptor (RA) Control Syringes and convenience kits containing the RA syringes.

In its February 25, 2026 earnings release furnished on Form 8-K, Medline highlighted that net income declined year over year, attributing pressure to tariffs and higher operating costs including IPO-related expenses.

Sources:

Medline Investor Relations, U.S. Food and Drug Administration, U.S. Securities and Exchange Commission

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$MDLN Insider Trading Activity

$MDLN insiders have traded $MDLN stock on the open market 28 times in the past 6 months. Of those trades, 4 have been purchases and 24 have been sales.

Here’s a breakdown of recent trading of $MDLN stock by insiders over the last 6 months:

GROUP INC. CARLYLE has made 0 purchases and 2 sales selling 45,242,173 shares for an estimated $1,625,293,097.
MOZART COINVESTMENT HOLDINGS, L.P. CARLYLE has made 0 purchases and 2 sales selling 45,242,173 shares for an estimated $1,625,293,097.
& FRIEDMAN CAPITAL PARTNERS X (PARALLEL), L.P. HELLMAN has made 0 purchases and 7 sales selling 32,219,608 shares for an estimated $1,231,240,883.
8 HOLDINGS MOZART MANAGER L.L.C. BCP has made 0 purchases and 4 sales selling 27,852,986 shares for an estimated $1,128,268,756.
MOZART ML-2 HOLDCO L.P. BX has made 0 purchases and 4 sales selling 27,852,986 shares for an estimated $1,128,268,756.
GROUP CAYMAN INVESTMENT HOLDINGS, L.P. TC sold 26,105,840 shares for an estimated $1,070,339,440
CIRCLE ML HOLDCO GP, LLC CP sold 26,105,840 shares for an estimated $1,070,339,440
PRIVATE LTD GIC has made 1 purchase buying 12,586,206 shares for an estimated $364,999,974 and 1 sale selling 10,204,351 shares for an estimated $289,480,090.
GROUP VII S1, L.L.C. TC sold 19,136,333 shares for an estimated $554,953,657
AGGREGATOR II LP MOZART sold 13,462,600 shares for an estimated $381,911,075
ANDREW J. MILLS purchased 2,586,206 shares for an estimated $74,999,974
CHARLES N. MILLS has made 2 purchases buying 2,579,310 shares for an estimated $74,799,990 and 0 sales.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

EARLY ACCESS

Receive MDLN Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$MDLN Hedge Fund Activity

We have seen 215 institutional investors add shares of $MDLN stock to their portfolio, and 2 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CARLYLE GROUP INC. added 215,303,036 shares (+inf%) to their portfolio in Q4 2025, for an estimated $9,042,727,512
H&F CORPORATE INVESTORS X, LTD. added 99,514,069 shares (+inf%) to their portfolio in Q4 2025, for an estimated $4,179,590,898
FMR LLC added 26,354,214 shares (+inf%) to their portfolio in Q4 2025, for an estimated $1,106,876,988
VANGUARD GROUP INC added 18,887,568 shares (+inf%) to their portfolio in Q4 2025, for an estimated $793,277,856
MORGAN STANLEY added 15,162,060 shares (+inf%) to their portfolio in Q4 2025, for an estimated $636,806,520
CAPITAL RESEARCH GLOBAL INVESTORS added 14,784,203 shares (+inf%) to their portfolio in Q4 2025, for an estimated $620,936,526
LONE PINE CAPITAL LLC added 11,716,697 shares (+inf%) to their portfolio in Q4 2025, for an estimated $492,101,274

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$MDLN Analyst Ratings

Wall Street analysts have issued reports on $MDLN in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

BTIG issued a "Buy" rating on 01/12/2026
RBC Capital issued a "Outperform" rating on 01/12/2026
Bernstein issued a "Outperform" rating on 01/12/2026
Wolfe Research issued a "Outperform" rating on 01/12/2026
Barclays issued a "Overweight" rating on 01/12/2026
Citigroup issued a "Buy" rating on 01/12/2026

To track analyst ratings and price targets for $MDLN, check out Quiver Quantitative's $MDLN forecast page.

$MDLN Price Targets

Multiple analysts have issued price targets for $MDLN recently. We have seen 23 analysts offer price targets for $MDLN in the last 6 months, with a median target of $50.0.

Here are some recent targets:

Patrick Donnelly from Citigroup set a target price of $60.0 on 03/11/2026
Lisa Gill from JP Morgan set a target price of $53.0 on 03/10/2026
David Larsen from BTIG set a target price of $55.0 on 03/09/2026
Ivan Feinseth from Tigress Financial set a target price of $60.0 on 03/09/2026
Patrick Wood from Morgan Stanley set a target price of $52.0 on 03/02/2026
Stephen Baxter from Wells Fargo set a target price of $47.0 on 02/27/2026
Ryan Halsted from RBC Capital set a target price of $53.0 on 02/26/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.